Related Experiment Video
Updated: Jun 13, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Effect of antipsychotic medications on glucose and lipid levels
Parminder S Chaggar1, Steven M Shaw, Simon G Williams
1Essex Cardiothoracic Centre, Basildon Hospital, Nethermayne, Basildon, SS16 5NL UK. pchaggar@doctors.org.uk
Abstract:
Severe mental illnesses, such as schizophrenia and bipolar affective disorder, are associated with excess cardiovascular morbidity and mortality. Cardiovascular risk in psychiatric disorders is partly related to antipsychotic therapy, especially second-generation or atypical antipsychotics. Some antipsychotic medications are associated with proatherogenic conditions including insulin resistance and dyslipidemia. In particular, olanzapine and clozapine have been consistently demonstrated to promote insulin resistance and dyslipidemia. Ziprasidone and amisulpiride may be associated with more favorable metabolic effects. Many of the published data relating to metabolic effects of anti-psychotics originate from retrospective studies. However, prospective randomized-controlled data are emerging, and the latest evidence is described here.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Psychosis and Antipsychotic Drugs: Overview
Mania and Antimanic Drugs: Overview
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Psychosis: Goals of Pharmacotherapy